Vaxart, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
Vaxart, Inc. (VXRT) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $70 for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-09.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2021-02-25
- Vaxart, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2019-03-31 was $70.00.
- Vaxart, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2018-12-31 was $0.00.
- Vaxart, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2018-09-30 was $0.00.
- Vaxart, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2018-06-30 was $140.00K.
- Vaxart, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2018 was $70.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2019-03-31 | $70.00 10-Q · filed 2019-05-09 | $70.00 derived: sum of 2 quarters · filed 2021-02-25 | $70.00 derived: sum of 3 quarters · filed 2021-02-25 | $140.07K derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $0.00 derived: sum of 2 quarters · filed 2021-02-25 | $140.00K derived: sum of 3 quarters · filed 2021-02-25 | $70.00K 10-K · filed 2021-02-25 | -$70.00K 10-K · filed 2019-02-06 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $140.00K derived: sum of 2 quarters · filed 2019-11-12 | $70.00K 10-Q · filed 2019-11-12 | -$70.00K 10-Q · filed 2018-11-13 | |||
| 2018-06-30 | $140.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $70.00K 10-Q · filed 2019-08-08 | -$70.00K 10-Q · filed 2018-08-10 | ||||
| 2018-03-31 | -$70.00K 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |